NASDAQ$CBUS
Cibus Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Announced financial results for the second quarter ended June 30, 2022.
Calyxt reported its Q2 2022 financial results, revealing nominal revenue of $41,000 compared to $11.9 million in the same quarter last year due to the completion of the wind-down of the Company’s soybean product line in late 2021. Net loss was $2.5 million, an improvement from $4.8 million in Q2 2021. The company's cash, cash equivalents, and restricted cash totaled $11.9 million as of June 30, 2022.
- Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95.
- 31 chemistries meet Calyxt’s target profile and several are the subject of term sheet discussions
- Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company
- Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale.
Headline financials
Revenue & EPS history
Cibus · Revenue · Quarterly
$41K
Forward guidance
Calyxt anticipates its cash runway to extend into early 2023, supported by disciplined cash management and proceeds from a February 2022 common stock and warrants offering.
Tailwinds
- Focused on product development activities using PlantSpring for BioFactory production.
- Advancing the licensing of patents and traits.
- Discussions with potential infrastructure partners are progressing.
- Infrastructure partners offer the potential to scale production for potential customers.
- Adopting an asset-lite approach that accelerates the speed in which Calyxt can bring chemistries to potential customers.
Headwinds
- Unspecified risks related to the company's filings with the SEC
- Impact of increased competition
- Competition for customers, partners, and licensees
- Disruptions at key facilities
- Flaws in AIML algorithms
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-1.1%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-12.4%
Avg return
30 days after
37%
13 / 35 earnings
Positive
+23.6%
Q4 2019
Best reaction
-25.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -10.3% | — | |
| Q4 2025 | -16.7% | -24.7% | -56.8% | |
| Q3 2025 | -0.8% | +1.6% | +28.8% | |
| Q2 2025 | -3.5% | -11.6% | -7.5% | |
| Q1 2025 | -7.8% | -8.1% | -29.4% | |
| Q4 2024 | -6.4% | -9.6% | -23.7% | |
| Q3 2024 | +14.5% | +15.2% | -8.9% | |
| Q2 2024 | -9.2% | +2.7% | -42.4% | |
| Q1 2024 | +2.2% | +9.5% | -37.5% | |
| Q4 2023 | -0.7% | +2.2% | +7.4% | |
| Q3 2023 | +17.0% | +5.0% | -8.8% | |
| Q2 2023 | -9.7% | -13.8% | -19.8% | |
| Q1 2023 | -3.6% | -8.3% | -15.8% | |
| Q4 2022 | +1.6% | -0.7% | -21.5% | |
| Q3 2022 | -1.4% | -7.7% | +22.5% | |
| Q2 2022 | +12.4% | +4.3% | -11.6% | |
| Q1 2022 | -17.3% | -27.4% | -60.0% | |
| Q4 2021 | -2.8% | -21.3% | -20.6% | |
| Q3 2021 | -7.4% | -9.0% | -41.9% | |
| Q2 2021 | +12.0% | +15.1% | +19.9% | |
| Q1 2021 | +4.6% | +3.3% | -17.4% | |
| Q4 2020 | -25.1% | -24.7% | -35.6% | |
| Q3 2020 | -1.4% | -4.0% | -44.3% | |
| Q2 2020 | -6.6% | +0.2% | -8.3% | |
| Q1 2020 | -15.0% | -9.4% | +27.9% | |
| Q4 2019 | +23.6% | +22.7% | -10.1% | |
| Q3 2019 | -9.7% | -10.2% | -16.3% | |
| Q2 2019 | +2.7% | -13.1% | -23.9% | |
| Q1 2019 | -3.5% | -6.7% | -9.3% | |
| Q4 2018 | +8.3% | +20.0% | +34.0% | |
| Q3 2018 | -2.9% | -4.9% | -22.1% | |
| Q2 2018 | -0.7% | -3.1% | -10.8% | |
| Q1 2018 | +1.9% | +22.1% | +28.1% | |
| Q4 2017 | +6.4% | +18.8% | +16.9% | |
| Q3 2017 | +7.8% | +8.2% | -2.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro